Abstract:Background: Treatment for pancreatic neuroendocrine tumors ( PNETs) in patients with unresectable metastatic liver disease has long been a controversial issue. This systematic review aims to summarize the existing evidence concerning the value of primary tumor resection in this group of patients. Methods: A systematic review of the literature and a meta-analysis were performed. The PubMed and Cochrane databases were searched to identify articles that compared palliative primary tumor resection and nonsurgical regimens in patients with PNETs and unresectable liver metastases. Relevant articles were identified in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA) guidelines. The primary outcome was overall survival. The included studies were evaluated for heterogeneity and publication bias. Results: Overall, 10 studies were included in the analysis. No randomized controlled trials ( RCTs) were identified. These studies included 1,226 patients who underwent a resection of the primary tumor and 1,623 patients who did not undergo surgery. The median overall survival was 36-137 and 13.2-65 months in the surgical and nonsurgical groups, respectively, and the 5-year overall survival rate was 35.7-83 and 5.4%-50%, respectively, in these two groups. The meta-analysis demonstrated that there was no significant difference in liver tumor burden ( odds ratio [ OR] = 1.51, 95% CI: 0.59-3.89, P=0.39) or tumor grade ( OR = 2.88, 95% CI: 0.92-9.04, P=0.07) among patients who underwent surgery and nonsurgical therapy. Furthermore, patients who underwent an aggressive surgical approach appeared to have a higher tumor grade. However, the meta-analysis demonstrated that patients who underwent primary tumor resection had better overall survival ( P<0.001), with a pooled hazard ratio of 0.36 ( 95% CI: 0.30-0.45). No publication bias was detected. Conclusion: This meta-analysis demonstrates that the palliative resection of the primary tumor in patients with PNETs and unresectable liver metastases can increase survival, although a bias toward a more aggressive surgical approach in patients with better performance status, less advanced disease, or a tumor located in the body or tail of the pancreas appears likely. RCTs with longer follow-up periods are required to confirm the advantages of palliative primary tumor resection for PNETs.

Surgical resection or palliative care for pancreatic cancer with liver oligometastasis

Surgical Techniques in the Radical Resection of Hilar Cholangiocarcinoma

[Surgical Treatment for Pancreatic Cancer with Liver Metastasis:Exploration and Innovation].

Time to Think: Selecting Patients Who May Benefit from Synchronous Resection of Primary Pancreatic Cancer and Liver Metastases

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis

The Management of Colorectal Cancer with Synchronous Liver Metastases

Highlights and difficulties in surgical treatment for pancreatic carcinoma

Role of Palliative Resection of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Metastatic Liver Disease: a Systematic Review and Meta-Analysis

[Treatment Strategies of Pancreatic Neuroendocrine Neoplasms with Liver Metastases].

[Controversies and Prospects for Surgical Treatment of Pancreatic Neuroendocrine Neoplasms with Liver Metastases].

The Role of Surgery in "Oligometastatic" Pancreas Cancer

Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

A retrospective analysis on survival factors of transarterial chemoembolization for patients of pancreatic carcinoma with liver metastasis

Prognostic Analysis of Combined Curative Resection of the Stomach and Liver Lesions in 30 Gastric Cancer Patients with Synchronous Liver Metastases

Current perspectives of comprehensive management of colorectal liver metastases

Clinical features and treatment strategies of liver metastases from pancreatic cancer

Advance of surgery for non-small-cell lung cancer with limited liver metastases

Surgical outcome of a resectable primary cancer of pancreas associated with another synchronous/metachronous resectable primary malignant tumor: a report of 13 patients and review of the literature

Surgical treatment for liver metastases of pancreatic neuroendocrine tumor

Simultaneous Resection of the Primary Tumour and Liver Metastases after Conversion Chemotherapy Versus Standard Therapy in Pancreatic Cancer with Liver Oligometastasis: Protocol of a Multicentre, Prospective, Randomised Phase III Control Trial (CSPAC-1)